Courtesy of Benzinga.
In a report published Monday, Credit Suisse analysts upgraded St Jude Medical, Inc. (NYSE: STJ) from Underperform to Neutral. The analysts expect the share price gains witnessed by Medtronic plc (NYSE: MDT) to diminish by mid-2015, while expecting upside to CardioMEMS sales in the long-term.
“While we expect CardioMEMS sales to be in line with guidance this year we see long-term upside based on our recently published survey. Moreover we expect Atrial Fibrillation & Neuromodulation to gain momentum over the course of the year, leaving around 5% CC sales growth after adjusting for missed selling days,” the analysts said.
Credit Suisse has also forecasted top-line acceleration for St Jude to close to 3.9 percent in FY15 from 2.0 percent in FY13, on the back of continued traction from FFR & OCT as well as new product launches. In fact, there could be further upside to the estimates in the longer-term if CardioMEMS witnesses stronger-than-anticipated uptake.
“We currently forecast $77M in 2015 CardioMEMS sales vs. guidance of $70M, but note that the Street’s anticipation for 2016 CardioMEMs sales will be determinative for the stock in the 2H of 2015,” the analysts added. However, the sales/EPS estimates for FY15 revised down due to worsening foreign exchange rates.
Latest Ratings for STJ
Date | Firm | Action | From | To |
---|---|---|---|---|
Apr 2015 | Credit Suisse | Upgrades | Underperform | Neutral |
Mar 2015 | Wells Fargo | Downgrades | Outperform | Market Perform |
Mar 2015 | Credit Suisse | Downgrades | Outperform | Underperform |
View More Analyst Ratings for STJ
View the Latest Analyst Ratings
Posted-In: Credit SuisseAnalyst Color Upgrades Analyst Ratings